Intercept Pharmaceuticals Director Sells $33,161,559 in Stock (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) Director Orbimed Advisors Llc unloaded 111,258 shares of the stock on the open market in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $298.06, for a total value of $33,161,559.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 1.54% on Wednesday, hitting $295.27. The stock had a trading volume of 229,932 shares. Intercept Pharmaceuticals has a 52-week low of $45.40 and a 52-week high of $497.00. The stock’s 50-day moving average is $247.1 and its 200-day moving average is $290.9. The company’s market cap is $6.265 billion. Intercept Pharmaceuticals also was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 595,961 shares, a decrease of 25.1% from the July 31st total of 795,445 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average daily volume of 1,067,623 shares, the days-to-cover ratio is presently 0.6 days.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. On average, analysts predict that Intercept Pharmaceuticals will post $-13.34 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday, August 15th. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday, August 14th. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday, August 12th. They now have a $456.00 price target on the stock, up previously from $323.00. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $472.91.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.